BioMarin Pharmaceutical

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

Funded from cash on hand, the purchase brings ALE1 into BioMarin’s rare-skeletal portfolio, signaling a push to scale clinical-stage therapies.